- Home
- ORMP vs ALRN Comparison
ORMP vs ALRN Comparison
Compare ORMP & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORMP
- ALRN
- Stock Information
- Founded
- ORMP 2002
- ALRN 2001
- Country
- ORMP United States
- ALRN United States
- Employees
- ORMP N/A
- ALRN N/A
- Industry
- ORMP Biotechnology: Pharmaceutical Preparations
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- ORMP Health Care
- ALRN Health Care
- Exchange
- ORMP Nasdaq
- ALRN Nasdaq
- Market Cap
- ORMP 94.2M
- ALRN 76.9M
- IPO Year
- ORMP N/A
- ALRN 2017
- Fundamental
- Price
- ORMP $2.31
- ALRN $2.58
- Analyst Decision
- ORMP Hold
- ALRN Strong Buy
- Analyst Count
- ORMP 1
- ALRN 1
- Target Price
- ORMP N/A
- ALRN $19.00
- AVG Volume (30 Days)
- ORMP 108.3K
- ALRN 87.4K
- Earning Date
- ORMP 12-03-2024
- ALRN 11-14-2024
- Dividend Yield
- ORMP N/A
- ALRN N/A
- EPS Growth
- ORMP N/A
- ALRN N/A
- EPS
- ORMP 0.11
- ALRN N/A
- Revenue
- ORMP N/A
- ALRN N/A
- Revenue This Year
- ORMP N/A
- ALRN N/A
- Revenue Next Year
- ORMP N/A
- ALRN N/A
- P/E Ratio
- ORMP $21.42
- ALRN N/A
- Revenue Growth
- ORMP N/A
- ALRN N/A
- 52 Week Low
- ORMP $2.00
- ALRN $1.61
- 52 Week High
- ORMP $3.67
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- ORMP 48.78
- ALRN 29.28
- Support Level
- ORMP $2.13
- ALRN $2.67
- Resistance Level
- ORMP $2.31
- ALRN $3.11
- Average True Range (ATR)
- ORMP 0.10
- ALRN 0.38
- MACD
- ORMP -0.00
- ALRN -0.15
- Stochastic Oscillator
- ORMP 60.00
- ALRN 4.85
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.